Safety first
Guide / Research briefs

Broad-Spectrum Photoprotection: The 2024 JEADV Review

Published October 30, 2026 · MTI Editorial Team · Sources linked on this page

!
Educational information only. Not medical advice and no dosing information. Melanotan I and II sold online are not FDA-approved. Talk to a licensed doctor.
Broad-Spectrum Photoprotection: The 2024 JEADV Review

Scientific perspectives on skin defense have expanded significantly beyond basic sunburn prevention. While avoiding acute redness was once the primary focus of sun safety, clinical research increasingly addresses the broader biological impacts of sunlight across diverse wavelengths. In wellness and tanning discussions, individuals sometimes turn to risky, unregulated substances such as melanotan I or melanotan II, which are sold online without medical approval or regulatory oversight. Rather than relying on unverified products, dermatologists point to peer-reviewed evidence to understand how solar energy affects skin tissues and how modern broad-spectrum measures actually function.

Study Scope and Context: The 2022 Dermatology Forum

To assess modern photoprotective measures and clinical disagreements, researchers published a review titled Photoprotection: Current developments and controversies. in the Journal of the European Academy of Dermatology and Venereology : JEADV in 2024. The publication summarized prominent topics analyzed during the dedicated photoprotection session at the International Forum of Dermatology in 2022.

The design of that international conference aimed to evaluate major clinical dermatology issues in a holistic manner, articulating multiple viewpoints across the medical community. Because of this structure, the authors noted specific parameters: the review does not claim to be exhaustive. Instead, it was organized as an expert overview outlining recent technological developments, biological mechanisms, and ongoing debates surrounding sun safety.

What the Study Found: Biological Damage Across the Solar Spectrum

The 2024 JEADV photoprotection review highlighted that cumulative ultraviolet radiation (UVR) exposure represents the primary aetiological factor behind photoageing, photoimunosuppression, and photocarcinogenesis. The authors detailed distinct pathways through which different wavelengths injure cutaneous cells:

  • UVB radiation (290-320 nm): Directly damages cellular DNA, triggering sunburns and inducing the formation of pyrimidine 6-4 pyrimidone photoproducts as well as 6-4 cyclobutane pyrimidine dimers (CPDs).
  • UVA radiation (320-400 nm): Penetrates deeper into the dermis. UVA harms DNA along with other intracellular and acellular structures primarily through the generation of reactive oxygen species (ROS). It acts as the primary driver of photoageing, resulting in fine and coarse wrinkles, dyspigmentation, and loss of skin elasticity.
  • Skin malignancies: Both UVA and UVB exposure independently increase the risk of basal cell carcinoma, squamous cell carcinoma, and melanoma.
  • Visible light (400-700 nm): Wavelengths in the visible light (VL) range are now recognized as contributors to conditions aggravated by solar exposure, specifically exacerbating hyperpigmentation and melasma.

What the Study Found: Emerging Filters and Comprehensive Defense

The review underscored that effective photoprotection is a critical health strategy to mitigate the harmful consequences of UVR and visible light. Adopting structured protective habits is essential for the prevention of photocarcinogenesis, drug-induced photosensitivity, and sunlight-induced or sunlight-exacerbated hyperpigmentation disorders.

On the technological front, newer sunscreens are incorporating advanced filters with absorption capacities extending beyond the traditional UV spectrum. These newer options deliver enhanced defense compared with older topical formulations. However, the study reiterated that topical products should never stand alone. A comprehensive photoprotection strategy requires combining multiple measures:

  • Remaining in the shade when outdoors.
  • Wearing photoprotective clothing.
  • Utilizing a wide-brimmed hat.
  • Wearing sunglasses to shield the eyes.
  • Applying broad-spectrum sunscreen products (as covered in our guide to sunscreen SPF and broad-spectrum coverage).

What the Study Does Not Prove: Filter Safety and Systemic Absorption

While discussing the evolution of modern formulations, the authors addressed active clinical debates regarding sunscreen ingredients. Due to the absorption of certain UV filters into the body, the overall safety of sunscreens has been questioned by critics and consumers alike.

Crucially, what the study does not prove is that sunscreen filters cause clinical illness, systemic toxicity, or long-term medical harm. The authors highlight filter absorption as an ongoing controversy and a focal point for discussion among clinicians, rather than a proven health danger. The review documents that the debate exists, but it does not establish evidence that using approved topical filters is unsafe or that patients should abandon photoprotection.

What the Data Does Not Prove: Total Immunity and Unregulated Peptides

It is equally important to clarify the limitations of broad-spectrum measures. While advanced filters absorb broader wavelengths, the study does not prove that any topical product provides complete immunity from solar radiation or permits unlimited midday sun exposure. Sunscreens diminish harm, but they do not eliminate cellular risks entirely.

Furthermore, the clinical review provides no evidence supporting unapproved systemic tanning agents. Black-market peptides like melanotan II are not recognized photoprotective strategies; they are unapproved, unregulated compounds that bypass standard clinical validation. For persistent pigmentation concerns, photodermatoses, or personalized skin cancer prevention, individuals should consult a board-certified dermatologist rather than relying on unverified online trends.

Sources

Photoprotection: Current developments and controversies. – Journal of the European Academy of Dermatology and Venereology : JEADV (PubMed PMID 38924160)

Published October 30, 2026. Sources are linked in the text. See our Medical Disclaimer.